Organization
Shire Plc
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Shire Plc
... The 2017 winner of this award is Stephen Listzwan, head of procurement, Shire Pharmaceuticals. The Innovation Award: This award is presented to the CPO that ...
... control of bleeding episodes1 Zug, Switzerland - November 13, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the world's leading biotechnology company in rare diseases, ...
... Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in ...
... Zug, Switzerland - Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in serving patients with rare ...
... 150 haematologists, the report covers 6 major therapies from CSL Behring, Pfizer, Shire, and Swedish Orphan Biovitrum. Top Takeaways Barriers affect a fifth of prescriptions: ...
... Shire plc (LSE: SHP, NASDAQ: SHPG) (the 'Company'), in accordance with 5.6.1R of the ...
... and Baxalta GmbH (collectively, with their affiliates, "Baxalta"), wholly-owned subsidiaries of Shire plc (LSE: SHP, NASDAQ: SHPG). Pursuant to the Sublicense Agreement, Xenetic granted to ...
... Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months ...
... Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others. The report also includes numerous ...
... exclusive license deal with, and a series of equity investments from, Shire plc (LSE: SHP, NASDAQ: SHPG) (formerlyBaxalta, Baxter Incorporated and Baxter Healthcare) to develop ...
... vice president, head of the US Internal Medicine and Oncology franchises for Shire. In this role, Mr. Hackman was a member of the US commercial ...
... recently Vice President, New Product Gene Therapy, Neuroscience, Oncology & Ophthalmology at Shire Plc., where she was developing and integrating strategies for Shire's gene therapy ...
... Shire is scrambling to take some manufacturing of its rare disease drug Cinryze ...
... Zug, Switzerland - Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in serving patients with rare ...
... Shire reports strong earnings growth in Q3 2017; reiterates full year guidance Product ...
... Shire shares have taken a beating this year, but they got a boost ...
... Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others. In conclusion, this report provides ...
... Shire Receives European Approval for Label Extension of FIRAZYR(R) (icatibant injection) for the ...
... most recently vice president, New Product Gene Therapy, Neuroscience, Oncology, Ophthalmology at Shire, Plc. "Andrea brings significant senior level executive experience leading global franchises in ...
... Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for ...
... Shire to Present New Data to Help Advance Understanding of Rare Diseases - ...
... -- AbbVie Inc. will have to face litigation that it defrauded a Shire PLC investor when it pulled out of a $55 million merger between ...
... the many activities, responsibilities and to-dos that make up a day, Shire plc (LSE: SHP, NASDAQ: SHPG) presentsCompose Your Life,an online and in-person activation that ...
... Reckitt also said it will split into two business units. Healthcare firm Shire was the worst faller, down 3.1 per cent after Citigroup removed it ...
... AMONG the products manufactured by Shire, the London-listed drugs group, are several treatments for Attention Deficit Hyperactivity Disorder. ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤